Psoriasis is a chronic, immune-mediated inflammatory skin disease that is associated with a high physical and psychosocial burden of disease. A skin biopsy specimen showed psoriasiform epidermal hyperplasia with hyperkeratosis and confluent parakeratosis. Investigational VEGF antagonists for psoriasis. Psoriasis and increased drug utilization: Ladoyanni E, Nambi R. Taken together, recognizing potential drug involvement in psoriasis is of clinical relevance to allow an optimal management of psoriasis. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation:
Register for email alerts with links to free full-text articles Access PDFs of free articles Manage your interests Save searches and receive search alerts. Home Journals Why publish with us? Her joint disease remains under good control. Exacerbation of psoriasis with beta-blocker therapy. Remission of psoriasis in a patient with hepatocellular carcinoma treated with sorafenib. Psoriasis and increased drug utilization: This work is published and licensed by Dove Medical Press Limited.
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
[Full text] Drug-induced psoriasis: clinical perspectives | PTT
New onset of aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNF-alpha antagonists: The first report of psoriasis exacerbation linked to lithium use dates from the s. The findings were consistent with psoriasis Figure 1 C. For permission for commercial use aalimumab this work, please see repodt 4. Serologic analysis revealed a positive antinuclear antibody ANA titer of 1: Upon discontinuation of the implicated drug, the psoriasis exacerbation can decrease ie, drug-induced psoriasis.
None, Conflict of Interest: Increased clinical awareness for medication-related causes of psoriasis induction or z should result in earlier recognition and treatment, which ultimately would lead to a better management in psoriasis treatment.
A skin biopsy specimen showed psoriasiform epidermal hyperplasia associated with parakeratosis, telangiectatic blood vessels, perivascular lymphocytic infiltrate, and occasional neutrophils in the papillary dermis and lower epidermis. However, in some cases, so-called psoriasiform skin lesions are described.
Drug-induced psoriasis: clinical perspectives
Psoriasis worsened by antimalarial prophylaxis.
Interferons have a well-known association with psoriasis development. Histologic findings, available in 20 of 43 cases, were consistent with psoriasis. Cutaneous eruptions were controlled with topical corticosteroid treatment alone or in combination with salicylic acid or calcipotriol in 18 patients data adalimumah for 25 patients.
Generalized pustular psoriasis and hepatic dysfunction ilterature with oral terbinafine therapy. Furthermore, rapid treatment withdrawal of systemic corticosteroids or potent topical corticosteroids may elicit a psoriasis flare ie, rebound effect. The etanercept and palmoplantarr regimens were discontinued, and treatment with topical steroids in combination with calcipotriol was started.
For instance, psoriasiform skin lesions may miss well-demarcated borders or lack the coarse scaling typical of psoriasis. Targeted therapy with biological agents has also provided new therapeutic options for patients with moderate to severe psoriasis. Of note, the available evidence supporting the associations of drug-related psoriasis with various drugs is limited predominantly to anecdotal single-case reports or retrospective case series.
Morphological psoriasis variants induced by TNF-alpha antagonists include plaque type psoriasis, pustular psoriasis, guttate psoriasis, scalp psoriasis, and palmoplantar psoriasis. Rituximab induced psoriasis in an infant.
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.
Patient 1, a year-old woman with rheumatoid arthritis, developed new-onset palmoplantar pustulosis after 26 months of etanercept therapy. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
The list of drugs that have associations with drug-related psoriasis is quite extensive. Psoriasis is a chronic, immune-mediated inflammatory skin disease that is associated with a high physical and psychosocial burden of disease.